Investors

SoftOx Wound & Skin Care AS is pleased to announce the successful completion of its recent Share Issue with oversubscription, raising the maximum targeted amount of NOK 6.6 million. The share price was NOK 0,005 per share. 

The company has also secured additional equity financing through a new convertible credit facility of NOK 12 million, which is conditional upon approval by the General Assembly. The drawn credit shall be converted to equity in the company at a share price of NOK 0,005 per share.  

The Board of Directors will recommend the General Assembly to offer a new repair share issue reflecting the NOK 12 million credit facility offered to a limited number of larger shareholders only. 

With this financing, the company is well-positioned to carry out a planned Phase 2 clinical study in Ukraine focused on antibiotic resistant wound infections, particularly in conflict zones, and to start the process for a potential listing on Nasdaq Capital Market in New York. 

A potential listing will be subject to approval from the General Assembly after PCOAB audits and completed listing application and will require additional financing of NOK 10 million up to IPO. A successful IPO will secure funding for the company’s planned Phase 3 clinical study. 

In parallel the Board explores potential commercialization of Wound Care’s products in Ukraine, to proof early adoption in a real-life market.  

The company would like to thank its shareholders for their continued trust and support as we take the next important steps in bringing our innovative wound care solutions to patients in need. 

Further details on the fully subscribed share issue: 

Reference is made to previous announcements in respect of the Share Issue of up to 1 321 735 178 new shares in SoftOx Wound & Skin Care AS (the “Company”).   

The subscription period in the Share Issue expired on 19 June 2025 at 16:30 (CEST). The Company received valid subscriptions for a total of 1 516 610 210 shares and was reduced to the maximum 1 321 735 178 Offer Shares. The Share Issue was therefore oversubscribed.  

The Share Issue comprises the issuance of 1 321 735 178 new shares at a subscription price of NOK 0,005 per new share (the “Offer Price”) with gross proceeds of approximately NOK 6 608 676.  

The Share Issue has been resolved pursuant to the authorization granted by the General Meeting 22 May 2025. The allocation is subject to approval from the board of directors. A board meeting for this purpose was held on the 30th of June 2025 and the Board approved the allocation of shares.  

The final allocation of the Offer Shares in the Share Issue has now been completed, and a total of 1 321 735 178 Offer Shares will, subject to timely payment, will be issued. The Offer Shares may not be transferred or traded until they are fully paid and the share capital increase pertaining to the Rights Issue has been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret).  The estimated date for delivery of shares tp the VPS accounts is medio August due to expected long processing time at the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). 

Following the issuance of the 1 321 735 178 Offer Shares, the Company’s share capital will be NOK 2 236 494,56, divided into 4 472 989 120 shares, each with a nominal value of NOK 0,0005. 

For further information, please contact:

Mail: post@sow.no